MR
MRNA
Quarter ended Jun 30, 2025 · FY2025 Q2

Moderna (MRNA) Revenue — Quarter Ended Jun 30, 2025

Moderna reported revenue growth in the current quarter compared to the immediately preceding quarter. However, revenue was lower than the same quarter one year earlier.

Key takeaway

Quarter ended Jun 30, 2025 · FY2025 Q2

Moderna reported revenue growth in the current quarter compared to the immediately preceding quarter. However, revenue was lower than the same quarter one year earlier.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$142M

Revenue reported for this quarter.

Quarter-over-quarter

+31.5%

Change from the immediately preceding quarter.

Year-over-year

-41.1%

Change from the comparable year-ago quarter.

Trailing four quarters

$3.1B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Sep 30, 2024$1.9B+1.7%
Dec 31, 2024$966M-65.6%
Mar 31, 2025$108M-35.3%
Jun 30, 2025$142M-41.1%

Revenue performance

Revenue increased from the prior quarter, reversing a recent downward trend.

Quarterly comparison

While revenue rose sequentially, it was significantly lower than the amount reported in the same quarter of the prior year.

What to watch

The sequential improvement may not indicate a sustained trend, given the substantial year-over-year decline.

Moderna (MRNA) Revenue — Quarter Ended Jun 30, 2025